Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × zimberelimab × 30 days × Clear all

Phase

Phase 2 9 Phase 1 4 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 49 Carboplatin 36 Specimen Handling 33 Magnetic Resonance Spectroscopy 30 Biopsy 30 Cyclophosphamide 29 Nivolumab 23 Dexamethasone 22 fludarabine 21 Gemcitabine 19 Bevacizumab 19 Paclitaxel 18 venetoclax 16 Pemetrexed 16 Rituximab 13 Cisplatin 13 atezolizumab 12 Temozolomide 12 Cetuximab 12 Azacitidine 12 Lenalidomide 11 Prednisone 10 Vincristine 9 Irinotecan 9 Fulvestrant 9 fludarabine phosphate 8 durvalumab 8 carfilzomib 8 aldesleukin 8 X-Rays 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡